Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial
COVID-19 감염이 있는 중환자 치료를 위한 Triiodothyronine: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] (therapeutic dose)
1:1
48 hour
48 hours
Acute myocardial infarction
addition
Administered
administration
adopted
allocation sequence
Alpha
Analysis
blinded
Blinding
Caregivers
clinical evidence
collected
comparator
conserved
copy
Corticosteroid
COVID-19
COVID-19 infected patient
COVID-19 infection
CRF
criterion
Critical
Critical illness
Critically ill
Critically ill patient
critically ill patients
database
defined
detect
Device
diagnosed
dissemination
dosage
dose
double-blind
drug
Drug administration
ECMO
effective
Efficacy and safety
element
enrolled
Estimated
EudraCT
excluded
extubation
favorable effect
female patient
Final
final analysis
Follow-up
followed by
Germany
Greece
group
hypoxia
hypoxic condition
hypoxic conditions
ICU
Identifier
Ill
illness
immune system
include
increased mortality
indicate
information
infusion
initiation of treatment
injection
intensive care unit
interim analysis
investigator
IWRS
less
Life expectancy
maintenance dose
MAPK
mechanical respiratory
mechanical ventilation
multi-organ dysfunction
number
objective
outcome
participant
Patient
performed
pharmacological treatment
Placebo
placebo controlled trial
Pregnancy
Primary outcome
protocol
Pulmonary infection
randomisation
randomised
randomised controlled trial
randomization
Randomized
recruited
recruitment
reveal
Sample size
Sepsis
severe systemic disease
signaling pathways
solution
Sponsor
status
study groups
Study protocol
subject
Support
systemic disease
therapeutic
therapeutic dose
Thyroid
thyroid hormone
tissue
trauma
Treatment
treatment allocation
Trial
Trial registration
triiodothyronine
unblinding
university
university hospital
ventilatory support
Version
Viral
viral infection
Viral load
website
with COVID-19
[DOI] 10.1186/s13063-020-04474-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04474-0 PMC 바로가기 [Article Type] Letter